Shattuck Labs IncNASDAQ:STTK
- LAST PRICE3.4900
- TODAY'S CHANGE (%)-0.3800 (-9.8191%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close3.8800 / 3.8700
- Day Range
- 52 Week Range
- Volume135,724
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | STTK |
|---|---|---|
| 09:32 ET | 12659 | 3.88 |
| 09:34 ET | 1000 | 3.854 |
| 09:38 ET | 400 | 3.9 |
| 09:39 ET | 2400 | 3.95 |
| 09:41 ET | 2059 | 3.9 |
| 09:43 ET | 200 | 3.9 |
| 09:45 ET | 4095 | 3.94 |
| 09:48 ET | 200 | 3.92 |
| 09:50 ET | 850 | 3.91 |
| 09:52 ET | 200 | 3.9 |
| 09:54 ET | 100 | 3.905 |
| 09:56 ET | 2996 | 3.88 |
| 09:57 ET | 200 | 3.89 |
| 10:01 ET | 200 | 3.89 |
| 10:03 ET | 100 | 3.9 |
| 10:06 ET | 200 | 3.9 |
| 10:08 ET | 100 | 3.885 |
| 10:12 ET | 100 | 3.905 |
| 10:14 ET | 100 | 3.9 |
| 10:15 ET | 659 | 3.88 |
| 10:21 ET | 200 | 3.88 |
| 10:24 ET | 100 | 3.89 |
| 10:26 ET | 100 | 3.89 |
| 10:28 ET | 500 | 3.88 |
| 10:30 ET | 100 | 3.87 |
| 10:32 ET | 200 | 3.89 |
| 10:33 ET | 100 | 3.9 |
| 10:35 ET | 400 | 3.8936 |
| 10:39 ET | 100 | 3.905 |
| 10:42 ET | 100 | 3.905 |
| 10:44 ET | 200 | 3.9 |
| 10:46 ET | 200 | 3.88 |
| 10:51 ET | 379 | 3.8722 |
| 10:55 ET | 800 | 3.89 |
| 10:57 ET | 190 | 3.87 |
| 11:02 ET | 100 | 3.9 |
| 11:04 ET | 100 | 3.9 |
| 11:06 ET | 100 | 3.89 |
| 11:08 ET | 100 | 3.905 |
| 11:09 ET | 100 | 3.91 |
| 11:11 ET | 100 | 3.89 |
| 11:13 ET | 100 | 3.9 |
| 11:15 ET | 100 | 3.905 |
| 11:20 ET | 100 | 3.905 |
| 11:24 ET | 100 | 3.905 |
| 11:26 ET | 100 | 3.905 |
| 11:27 ET | 100 | 3.89 |
| 11:31 ET | 100 | 3.9 |
| 11:33 ET | 100 | 3.89 |
| 11:36 ET | 100 | 3.89 |
| 11:38 ET | 200 | 3.86 |
| 11:42 ET | 100 | 3.86 |
| 11:44 ET | 100 | 3.86 |
| 11:47 ET | 100 | 3.86 |
| 11:51 ET | 100 | 3.86 |
| 11:54 ET | 100 | 3.845 |
| 11:58 ET | 100 | 3.83 |
| 12:09 ET | 200 | 3.81 |
| 12:14 ET | 100 | 3.82 |
| 12:21 ET | 100 | 3.82 |
| 12:25 ET | 100 | 3.83 |
| 12:30 ET | 600 | 3.805 |
| 12:32 ET | 100 | 3.805 |
| 12:34 ET | 116 | 3.795 |
| 12:36 ET | 1200 | 3.775 |
| 12:48 ET | 100 | 3.78 |
| 01:01 ET | 100 | 3.75 |
| 01:03 ET | 100 | 3.755 |
| 01:28 ET | 100 | 3.735 |
| 01:35 ET | 100 | 3.7 |
| 01:39 ET | 200 | 3.7 |
| 01:50 ET | 800 | 3.66 |
| 01:51 ET | 200 | 3.64 |
| 01:55 ET | 900 | 3.6516 |
| 01:57 ET | 100 | 3.655 |
| 02:15 ET | 204 | 3.65 |
| 02:22 ET | 836 | 3.62 |
| 02:24 ET | 100 | 3.62 |
| 02:26 ET | 300 | 3.59 |
| 02:31 ET | 793 | 3.59 |
| 02:33 ET | 100 | 3.58 |
| 02:36 ET | 200 | 3.59 |
| 02:38 ET | 100 | 3.605 |
| 02:42 ET | 1371 | 3.62 |
| 02:45 ET | 100 | 3.62 |
| 02:47 ET | 200 | 3.63 |
| 02:51 ET | 100 | 3.62 |
| 02:54 ET | 100 | 3.61 |
| 03:00 ET | 374 | 3.595 |
| 03:02 ET | 948 | 3.575 |
| 03:03 ET | 223 | 3.57 |
| 03:07 ET | 500 | 3.56 |
| 03:12 ET | 100 | 3.58 |
| 03:18 ET | 304 | 3.55 |
| 03:20 ET | 108 | 3.555 |
| 03:21 ET | 100 | 3.56 |
| 03:23 ET | 212 | 3.56 |
| 03:25 ET | 1634 | 3.54 |
| 03:27 ET | 300 | 3.54 |
| 03:32 ET | 212 | 3.545 |
| 03:34 ET | 11280 | 3.5 |
| 03:36 ET | 552 | 3.51 |
| 03:38 ET | 500 | 3.51 |
| 03:39 ET | 513 | 3.52 |
| 03:41 ET | 1300 | 3.52 |
| 03:43 ET | 200 | 3.52 |
| 03:45 ET | 580 | 3.53 |
| 03:48 ET | 1750 | 3.535 |
| 03:50 ET | 300 | 3.54 |
| 03:52 ET | 1569 | 3.535 |
| 03:54 ET | 1987 | 3.53 |
| 03:56 ET | 954 | 3.53 |
| 03:57 ET | 3850 | 3.52 |
| 03:59 ET | 29346 | 3.49 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Shattuck Labs Inc | 181.8M | -1.9x | --- |
Inovio Pharmaceuticals Inc | 176.8M | -1.1x | --- |
Skye Bioscience Inc | 182.0M | -1.0x | --- |
Cytodyn Inc | 182.2M | -3.0x | --- |
Galectin Therapeutics Inc | 178.7M | -3.5x | --- |
Atossa Therapeutics Inc | 191.2M | -7.4x | --- |
Company Information
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
Contact Information
- Headquarters
- 500 W. 5Th Street, Suite 100AUSTIN, TX, United States 78701
- Phone
- 512-900-4690
- Fax
- ---
Executives
- Independent Chairman of the Board
- George Golumbeski
- Chief Executive Officer, Co-Founder, Director
- Taylor Schreiber
- Chief Financial Officer
- Andrew Neill
- General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
- Stephen Stout
- Chief Business Officer
- Casi Deyoung
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $166.6M |
|---|---|
Revenue (TTM) | $4.1M |
Shares Outstanding | 47.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.73 |
EPS | $-1.85 |
Book Value | $3.06 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | 40.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,195.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
